Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes

A method of treating a subject with a therapeutic agent that treats or inhibits a kidney disease wherein the subject has a kidney disease, or preventing a subject from developing a kidney disease by administering a therapeutic agent that prevents a kidney disease, the method comprising the steps of:

• determining whether the subject has any one or more variant nucleic acid molecules encoding an Aldehyde Dehydrogenase 1 Family Member L1 (ALDH1L1), a Fructose-Bisphosphate Aldolase B (ALDOB), a Glucose-6-Phosphatase Catalytic Subunit 1 (G6PC), an LDL Receptor Related Protein 2 (LRP2), a Ribosomal Protein L3 Like (RPL3L), a Solute Carrier Family 25, Member 4 (SLC25A45), or a Solute Carrier Family 7 Member 9 (SLC7A9) predicted loss-of-function polypeptide by:
• obtaining or having obtained a biological sample from the subject;
• and
• performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising any one or more of ALDH1L1, ALDOB, G6PC, LRP2, RPL3L, SLC25A45, or SLC7A9 variant nucleic acid molecules encoding a predicted loss-of-function polypeptide;
• and
• administering or continuing to administer the therapeutic agent that treats, prevents, or inhibits the kidney disease in an amount that is the same as or less than a standard dosage amount to a subject that is ALDH1L1, ALDOB, G6PC, LRP2, RPL3L, SLC25A45, and SLC7A9 reference, and/or administering one or more ALDH1L1 inhibitors, ALDOB inhibitors, G6PC inhibitors, LRP2 inhibitors, RPL3L inhibitors, SLC25A45 inhibitors, or SLC7A9 inhibitors, or any combination thereof, to the subject;
• administering or continuing to administer the therapeutic agent that treats, prevents, or inhibits the kidney disease in an amount that is the same as or less than a standard dosage amount to a subject that is heterozygous for any one or more of ALDH1L1, ALDOB, G6PC, LRP2, RPL3L, SLC25A45, or SLC7A9 variant nucleic acid molecules, and/or administering one or more ALDH1L1 inhibitors, ALDOB inhibitors, G6PC inhibitors, LRP2 inhibitors, RPL3L inhibitors, SLC25A45 inhibitors, or SLC7A9 inhibitors, or any combination thereof, to the subject;
• or
• administering or continuing to administer the therapeutic agent that treats, prevents, or inhibits the kidney disease in a standard dosage amount to a subject that is homozygous for any one or more of ALDH1L1, ALDOB, G6PC, LRP2, RPL3L, SLC25A45, or SLC7A9 variant nucleic acid molecules;
• wherein the presence of a genotype having one or more of ALDH1L1, ALDOB, G6PC, LRP2, RPL3L, SLC25A45, or SLC7A9 variant nucleic acid molecules indicates the subject has a decreased risk of developing the kidney disease.